MB
ALKS icon

MPM BioImpact’s Alkermes ALKS Stock Holding History

MPM BioImpact’s Portfolio ALKS Stock Details ALKS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-549,262
Closed -$16.5M – 40
2025
Q3 		$16.5M Hold
549,262
– – 2.7% 15
2025
Q2 		$15.7M Buy
549,262
+211,659
+63% +$6.3M 2.72% 12
2025
Q1 		$11.1M Buy
+337,603
New +$11M 1.92% 20
2024
Q3 		– Sell
-557,556
Closed -$13.4M – 44
2024
Q2 		$13.4M Buy
+557,556
New +$13.7M 2.09% 14

Other funds holding ALKS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's ALKS Position: Q4 2025 in Review

MPM BioImpact sold out of Alkermes (ALKS) in Q4 2025, closing a stake of 549,262 shares — an estimated $16.5M sold.

MPM BioImpact first reported a position in ALKS in Q2 2024 and held it in 4 quarters. The position peaked at $16.5M in Q3 2025. 366 funds tracked by Wall St. Rank hold ALKS as of Q4 2025.

  • MPM BioImpact reported no remaining Alkermes position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 549,262 Alkermes shares in Q4 2025, an estimated $16.5M.
  • MPM BioImpact first reported a position in Alkermes in Q2 2024 and held it in 4 quarters.
  • MPM BioImpact's Alkermes position peaked at $16.5M in Q3 2025.
  • 366 funds tracked by Wall St. Rank held Alkermes as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.